Improve Healthy Ageing in Seniors; Prevent Disease at Older Age
Conditions
Brief summary
The European population is aging rapidly which poses a challenge on the individual, the European societies, and health care systems. Among the most promising public health interventions that may extend healthy life expectancy at older age are vitamin D, marine omega-3 fatty acids and physical exercise. However, their individual and combined effects have yet to be confirmed in a clinical trial. The broad aim of DO-HEALTH is to prolong healthy life expectancy in European seniors. The specific aim is to establish whether vitamin D, omega-3 fatty acids, and a simple home exercise program will prevent disease at older age. To achieve these aims, DO-HEALTH will enroll 2152 community-dwelling men and women who are 70 years and older, an age when chronic diseases increase substantially. The DO-HEALTH seniors will be recruited from 7 European cities (Zurich, Basel, Geneva, Toulouse, Berlin, Innsbruck and Coimbra) and will be randomized in a 2x2x2 factorial design trial to a simple home exercise program and/or vitamin D, and/or omega-3 fatty acids, over a 3 year period. This will allow to test the individual and the combined benefit of the interventions in the prevention of 5 primary endpoints: incident non-vertebral fractures; functional decline; systolic and diastolic blood pressure change; cognitive decline; and the rate of any infection. Key secondary endpoints include incidence of hip fractures, rate of falls, severity of pain in symptomatic knee osteoarthritis, gastro-intestinal symptoms, mental and oral health, quality of life, and mortality. All clinical endpoints will be supported by a large DO-HEALTH biomarker study to evaluate the effect of the interventions at the cellular level of multi-organ function. DO-HEALTH will further evaluate reasons why or why not seniors adhere to the 3 interventions, and will assess their cost-benefit in a health economic model based on documented health care utilization and observed incidence of chronic disease. website DO-HEALTH: http://do-health.eu/wordpress/
Detailed description
The 3 primary treatment comparisons are: 1. 2000 IU vitamin D per day compared to placebo (controlling for the other treatment strategies) 2. 1 g of omega-3 fatty acids (EPA+DHA, ratio 1:2, from marine algae) compared to placebo (controlling for the other treatment strategies) 3. Home exercise program (muscle strength) of 30 minutes 3 times a week compared to a control exercise program (joint flexibility) 30 minutes 3 times a week Follow-up: DO-HEALTH seniors will be followed for 3 years, in-person, and in 3-monthly intervals (4 clinical visits and 9 phone calls) at the 7 recruitment centers. Study population: DO-HEALTH will enroll seniors age 70 years and older. To represent the largest part of the senior population, DO-HEALTH will recruit community-dwelling seniors. However, to represent also the pre-frail population at risk of institutionalization, at least 40% of seniors will be enrolled based on a fall with or without a fracture in the year before DO-HEALTH enrolment. Study Design: This is a randomized, double-blind, placebo-controlled, 2×2×2 factorial design clinical trial. Recruitment Centers: The trial will be performed at 7 recruitment centers located in 5 countries: Switzerland (University of Zurich, Basel University Hospital, Geneva University Hospital), France (University of Toulouse Hospital Centre), Germany (Charité Berlin), Portugal (University of Coimbra), and Austria (Innsbruck Medical University). Randomization: Stratified block randomization. Labeling of study intervention will be performed by a central randomization centre in Switzerland. Stratification variables: recruitment centre (7 centers), fall during previous 12 months (yes/no), gender, and age (70 - 84 and 85+). At least 40% of Seniors among those who fell or did not fall during the last year will be enforced at each of the 7 recruitment centers. Gender and age distribution will be monitored within each recruitment centre with the DO-HEALTH randomization software. If gross imbalance (less than 30% of fallers/non-fallers in a stratum) is detected within a centre, recruitment strategies for the centre will be adapted to boost recruitment of participants of underrepresented category. website DO-HEALTH: http://do-health.eu/wordpress/
Interventions
2000 IU/d
Ratio EPA:DHA = 1:2 1 g/d
Sponsors
Study design
Eligibility
Inclusion criteria
* Age 70 years or older * Mini Mental State Examination Score of at least 24 * Living in the community * Sufficiently mobile to come to the study centre * Able to walk 10 meters with or without a walking aid and able to get in and out of a chair without help * Able to swallow study capsules * Able and willing to participate, sign informed consent (including consent to analyze all samples until drop-out or withdrawal) and cooperate with study procedures
Exclusion criteria
* Consumption of more than 1000 IU vitamin D/day in the 36 months prior to enrollment, or a bolus of 300'000 IU or more in the last 12 month prior to enrollment, and/ or unwillingness to limit vitamin D intake to the current standard of 800 IU/day of vitamin D during the course of the trial. Provision 1: an individual who consumed an average vitamin D dose between 1000 and 2000 IU vitamin D/day in the 3 months prior to enrollment, may be enrolled after a 3-month wash-out period where the maximum daily intake is limited to 800 IU vitamin D. Provision 2: an individual who consumed an average vitamin D dose higher than 2000 IU/day in the 3 months prior to enrollment, may be enrolled after a 6-month wash-out period where the maximum daily intake is limited to 800 IU vitamin D. * Unwillingness to limit calcium supplement dose to 500 mg per day for the duration of the trial * Taking omega-3 fat supplements in the 3 month prior to enrolment and unwilling to forgo their use for the duration of the trial * Use of any active vitamin D metabolite (i.e. Rocaltrol, alphacalcidiol), PTH treatment (i.e. Teriparatide), or Calcitonin at baseline and unwillingness to forego these treatments during the course of the trial * Current or recent (previous 4 months) participation in another clinical trial, or plans of such participation in the next 3 years (corresponding to DO-HEALTH length) * Presence of the following diagnosed health conditions in the last 5 years: history of cancer (except non-melanoma skin cancer); myocardial infarction, stroke, transient ischemic attack, angina pectoris, or coronary artery intervention * Severe renal impairment (creatinine clearance = 15 ml/min) or dialysis, hypercalcaemia (\> 2.6 mmol/l) * Hemiplegia or other severe gait impairment * History of hypo- or primary hyperparathyroidism * Severe liver disease * History of granulomatous diseases (i.e. tuberculosis, sarcoidosis) * Major visual or hearing impairment or other serious illness that would preclude participation * Living with a partner who is enrolled in DO-HEALTH (i.e. only one person per household can be enrolled) * Living in assisted living situations or a nursing home * Temporary exclusion: acute fracture in the last 6 weeks * Epilepsy and/or use of anti-epileptic drugs * Individuals who fell more than 3 times in the last month * Osteodystrophia deformans (M. Paget, Paget's disease) * For study centers in Germany only: persons who are institutionalized / in prison by court order (§40, Abs. 1, Art. 4, Gesetz über den Verkehr mit Arzneimitteln).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Bone: Incident non-vertebral fractures over 36 months | over 36 months | Confirmed by medical and/or x-ray reports |
| Immunity: Rate of any infections | Baseline, and every 3 months up to 36 months | 3-monthly incident infection protocol |
| Brain: Cognitive decline | Baseline, 12, 24 and 36 months | Montreal Cognitive Assessment (MoCA) |
| Cardio-vascular: Systolic and diastolic blood pressure change | Baseline, 12, 24 and 36 months | Standardized blood pressure assessment in sitting position |
| Muscle: Functional decline (lower extremity function) | Baseline, 12, 24 and 36 months | Measured with the SPPB (short physical performance test battery) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Global Health: Mortality | 36 months | — |
| Dental: Decline in oral health | Baseline, 12,24 and 36 months | Assessed with questionnaire. |
| Dental: Tooth loss | 36 months | Assessed by tooth count at every clinical visit |
| Gastro-Intestinal: rate of GI symptoms | Baseline, 12, 24 and 36 months | Assessed with ROME III questionnaire. |
| Glucose-Metabolic: Change in fasting glucose, insulin levels (QUICKI, HOMA index) | Baseline, 12,24,36 months | Laboratory measures at the Central DO-HEALTH Laboratory (Institute of Clinical Chemistry at the University Hospital Zurich) |
| Glucose-Metabolic: Body composition | Baseline, 12, 24, 36 months | Subset of 1502 participants with DXA measurements |
| Kidney: Decline in kidney function | Baseline, 12, 24, and 36 months | Blood creatinine levels and estimated glomerular filtration rate |
| Global Health: Quality of life | Every 6 months | Assessed with questionnaire (EuroQuol). |
| Global Health: Incident disability regarding activities of daily living | Baseline, 12, 24 and 36 months | Assessed with HAQ-PROMIS questionnaire |
| Global Health: Incident nursing home admission | 36 months | — |
| Bone: Incident hip fractures | 36 months | Based on medical records and/or x-ray reports |
| Bone: Incident total fractures | 36 months | Combined non-vertebral and vertebral fractures among subgroup of 1502 participants with DXA vertebral morphometry assessment |
| Bone: Incident vertebral fractures | 36 months | Based on DXA vertebral morphometry among subset of 1502 participants |
| Bone: Bone mineral density decrease at the lumbar spine and hip | Baseline, 12, 24, and 36 months | Assessed in a subset of 1502 participants with DXA measurements |
| Muscle: Rate of falls | Assessed every 3 months over 36 months | Any low trauma fall, injurious fall |
| Muscle: reaction time and grip strength | Baseline, 12,24,36 months | Reaction time will be assessed with the repeated sit-to-stand test; grip strength will be assessed with the Martin Vigorimeter |
| Muscle: Muscle mass decrease at upper and lower extremities | Baseline, 12,24,36 months | Subset of 1502 participants with DXA measurements |
| Muscle: Dual tasking 10-meter gait speed | Baseline, 12,24 and 36 months | — |
| Muscle/Bone: musculoskeletal pain | Baseline, 12,24, and 36 months | Assessed with the McGill questionnaire |
| Cardio-vascular: Incident Hypertension | 36 months | — |
| Brain: mental health decline | Baseline, 12,24, and 36 months | Assessed with Geriatric Depression Scale |
| Brain: Incident Depression | 36 months | — |
| Brain/Muscle: Dual tasking gait variability | Baseline, 12, 24 and 36 months | Subset of 250 participants |
| Immunity: Rate of upper respiratory infections / rate of flu-like illness | 36 months | Assessed with infection protocol every 3 months |
| Immunity: Incident severe infections that lead to hospital admission | 36 months | — |
| Cartilage/Bone: Severity of knee pain in participants with symptomatic knee osteoarthritis | Baseline, 12, 24 and 36 months | Assessed with the KOOS questionnaire. Knee OA assessment with modified ACR criteria. |
| Cartilage/Bone: Rate of knee buckling | Baseline, 12,24,36 months | Questionnaire-based. |
| Cartilage/Bone: NSAID use / number of joints with pain | Baseline, 12, 24, 36 months | Assessed by questionnaire and homunculus figure |
Other
| Measure | Time frame | Description |
|---|---|---|
| Immunity: Incident cancer / rate of implant infections / rate of gastro-intestinal infections | 36 months | Incident cancer (any cancer, gastro-intestinal, breast cancer in women, prostate cancer in men); rate of implant infections after total hip or knee replacement (due to fracture or osteoarthritis); rate of gastro-intestinal infections |
| Cartilage/bone: Incident osteoarthritis | Baseline, 12, 24, and 36 months | Incident symptomatic knee osteoarthritis; incident symptomatic hip osteoarthritis, incident symptomatic hand osteoarthritis; composite endpoint: incident symptomatic knee, hip or hand osteoarthritis; severity of hip pain in those with prevalent symptomatic hip osteoarthritis, severity of hand pain in those with prevalent symptomatic hand osteoarthritis |
| Adherence laboratory | Baseline, 12, 24, and 36 months | Serum 25(OH)D concentrations (measured both by an automated assay and HPLCMS/MS) and plasma PUFA concentrations (EPA, AA, DPA, DHA; measured by a sensitive and selective assay based on gas chromatography coupled to mass spectrometry detection (GC-MS)) in all participants |
| Muscle: Incident sarcopenia / incident frailty / decline in physical function | 36 months | Incident sarcopenia (among subset of 1502 seniors with yearly DXA measurements), incident frailty (questionnaire), decline in physical activity (questionnaire) |
| BONE: Functional recovery after long bone fracture | 36 months | — |
| Bone: Incident repeat fractures | 36 months | Any repeat non-vertebral fractures in all participants, vertebral fractures and total fractures among subset of 1502 seniors with yearly DXA measurements |
| Biomarker endpoints | Baseline, 12, 24, and 36 months | — |
| Brain: incident dementia | 36 months | — |
| Cardio-vascular: Major cardio-vascular events | 36 months | Major cardiovascular events as a composite endpoint (any event: myocardial infarction, stroke, revascularization procedures of CABG and PCI, incident congestive heart disease, cardiovascular mortality); individual endpoints: myocardial infarction, stroke, incident congestive heart disease, and cardiovascular mortality (assessed every 3 months over 36 months) |
Countries
Austria, France, Germany, Portugal, Switzerland